GSK

The alliance's first aim is the identification, development, and validation of biomarkers of cancer and treatment response.

The firms will have exclusive access for a limited time to the data from the first 50,000 individuals with samples in the biobank to be sequenced.

The study seeks to identify biomarkers that can help personalize treatment for patients by identifying signs of rapid decline in kidney function.

Therapies aimed at drug targets that have been linked genetically to disease fare better through the drug development pipeline, researchers from GSK and elsewhere found.

The institute will develop new technologies and approaches to decode how genes are controlled and how a cell's "operating system" functions.